AU2017201076B2 — Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Assigned to Bristol Myers Squibb Co · Expires 2018-11-15 · 8y expired
What this patent protects
Compounds having the following formula I: R1, 'j or a stereoisomer or pharmaceutically-acceptable salt thereof, where RI, R 2, R3 , R 4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNu, by acting on Tyk-2 to cause signal transduction inhibit…
USPTO Abstract
Compounds having the following formula I: R1, 'j or a stereoisomer or pharmaceutically-acceptable salt thereof, where RI, R 2, R3 , R 4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNu, by acting on Tyk-2 to cause signal transduction inhibition. - 208 -
Drugs covered by this patent
- Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.